19:34 , May 17, 2018 |  BC Innovations  |  Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
22:22 , Jan 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Worm and mouse studies suggest promoting NAD+ synthesis could help treat AD. In a worm model of AD, the NAD+ precursor nicotinamide riboside or the PARP inhibitor Lynparza olaparib, which blocks...
03:19 , Jan 19, 2018 |  BC Innovations  |  Strategy

After amyloid

As the Alzheimer’s field is slowly taking on the search for new targets outside of the β amyloid and tau hypotheses, researchers are ramping up exploration of new pathways and looking to the disease’s genetics...
19:53 , Oct 12, 2017 |  BC Innovations  |  Translation in Brief

Opening doors for I-O

A Science Translational Medicine study has flipped the script for tumor lymphangiogenesis by turning VEGF-C, a hallmark of poor prognosis, into a biomarker and a target for successful responses to immunotherapies. Tumors that are surrounded by...
19:40 , Oct 3, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Serum levels of VEGF-C could help predict responses to immunotherapies in patients with solid tumors. In sera from 20 metastatic melanoma patients vaccinated with melan-A (MLANA; MART1) peptide and the toll-like receptor 9...
18:07 , Aug 29, 2017 |  BC Innovations  |  Distillery Techniques

Drug platforms; drug properties

TECHNOLOGY: Peptides; pharmacokinetics/pharmacodynamics; physicochemical properties A palmitoylated heptapeptide could be used to enhance the stability and serum half-lives of therapeutic peptides. The heptapeptide consisted of an amino acid sequence containing four glutamic acid residues for enhanced...
22:23 , Jul 20, 2017 |  BC Extra  |  Preclinical News

Team develops conjugation strategy for longer-lived peptides

In a Nature Communications paper, a research team led by Christian Heinis at the Ecole Polytechnique Federale de Lausanne (EPFL) showed that conjugating a peptide-fatty acid construct to therapeutic peptides could extend their half-lives substantially....
16:20 , Jun 20, 2017 |  BC Innovations  |  Distillery Therapeutics

Other

INDICATION: Genetic disorders Patient sample and mouse studies suggest inhibiting COL6A1 could help treat hyaline fibromatosis syndrome (HFS), which is caused by ANTXR2 mutations. In patients, levels of COL6A1 were higher in HFS skin nodules than...
20:15 , May 25, 2017 |  BC Innovations  |  Finance

Europe’s translational springtime

European science is showing early signs of translational growth, with VCs increasingly shifting their focus to preclinical assets. But investors are concerned the region still doesn’t have the supply of management talent or funding it...
22:57 , Apr 7, 2017 |  BioCentury  |  Emerging Company Profile

Up a notch

By targeting a protein all Notch receptors use to turn on oncogenes, Cellestia Biotech AG’s molecules could treat more patients than therapies against individual Notch receptors or ligands, with less toxicity than other pan-Notch inhibitors. The...